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Gallstone Disease and the Risk  
of Cardiovascular Disease
Cameron J. Fairfield  , stephen J. Wigmore  & ewen M. Harrison
Gallstone disease (GD) is one of the most common presentations to surgical units worldwide and 
shares several risk factors with cardiovascular disease (CVD). CVD remains the most common cause 
of death worldwide and results in considerable economic burden. Recent observational studies have 
demonstrated an association between GD and CVD with some studies demonstrating a stronger 
association with cholecystectomy. We present the findings of a meta-analysis assessing the relationship 
between GD and CVD. A total of fourteen cohort studies with over 1.2 million participants were 
included. The pooled hazard ratio (HR, 95% confidence interval [CI]) for association with GD from a 
random-effects model is 1.23 (95%CI: 1.16–1.30) for fatal and non-fatal CVD events. The association 
was present in females and males. three studies report the relationship between cholecystectomy and 
CVD with a pooled HR of 1.41 (95%CI: 1.21–1.64) which compares to a HR of 1.30 (95%CI: 1.07–1.58) 
when cholecystectomy is excluded although confounding may influence this result. Our meta-analysis 
demonstrates a significant relationship between GD and CVD events which is present in both sexes. 
Further research is needed to assess the influence of cholecystectomy on this association.
Cardiovascular disease (CVD) remains the most common cause of death worldwide1–3. Despite significant 
advances in the prevention and treatment of CVD, the societal and economic burden is considerable and con-
tinues to rise4. CVD is preventable and it is cost-effective to promote risk factor modification in those at risk of 
CVD5. Early identification of at-risk populations may allow these changes to be implemented at a time when they 
are most effective.
Gallstone disease (GD) forms one of the most common presentations to surgical units worldwide6–8 and 
patients with gallstones have a higher prevalence of risk factors for cardiovascular disease including obesity 
and elements of the metabolic syndrome9,10. The presence of gallstones is associated with atherosclerosis11 and 
patients with gallstones may be at high risk of progression to symptomatic CVD.
Several observational studies have been published reporting a link between GD and CVD although some 
studies have found no difference12–22. While recent meta-analyses have demonstrated an association between 
GD and CVD, there is significant variation in the effect size of contributing studies. No meta-analysis to date has 
adequately accounted for confounding and the heterogeneity remains unexplained21,23,24. Further uncertainty is 
present over the role of cholecystectomy in modifying the risk of CVD with some authors concluding that chole-
cystectomy may directly cause CVD24. Analyses of cholecystectomy and CVD have not sufficiently accounted for 
the presence of confounding variables such as gallstone severity and inflammation. It is likely that these factors 
account for any apparent association between cholecystectomy and CVD. An additional cohort study examining 
the relationship between screen-detected GD and CVD has also been published with assessment of the impact of 
cholecystectomy on CVD22.
We therefore undertook a systematic review with meta-analysis of longitudinal studies assessing the impact 
of GD on CVD. We performed additional analyses assessing the impact of cholecystectomy on this association.
Results
search Results. The search identified 5497 references of which 984 were duplicates. Searching of bibliogra-
phies identified six other potentially relevant references. Following screening of titles and abstracts, 118 articles 
remained for full text review. After exclusion of 93 articles (not longitudinal studies, not including GD or not 
including CVD), a total of 25 citations referring to fourteen cohort studies were included in this systematic review 
(Fig. 1). One publication reported two cohort studies14 and one publication reported three separate cohort studies 
as well as a meta-analysis21. Two cohort studies included participants recruited from the same National Health 
Insurance Research Database (Taiwan) and recruited controls from overlapping inclusion periods17,18. To prevent 
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bias in our meta-analysis we conducted all analyses twice: first using the larger of the two studies18 and second 
using the smaller study17. We present results from the first set of analyses and describe any differences from the 
second set of analyses.
study Characteristics. There were 14 prospective and retrospective cohort studies reported in eleven pri-
mary publications and reported in a further fourteen duplicate publications including conference abstracts. The 
characteristics of the studies are reported in Table 1. Two studies reported CVD mortality, seven studies reported 
coronary heart disease (CHD), one study reported cerebrovascular disease and four studies reported multiple 
CVD outcomes. Four studies relied on baseline ultrasound for diagnosis of GD, one study used cholecystography, 
two studies used International Classification of Disease (ICD) database records of GD verified in hospital records, 
five studies used self-reported GD at baseline with four of these verifying reports through hospital records and 
two studies do not report on ascertainment of exposure to GD and define exposure as “gallbladder disease” rather 
than GD. Both of the studies which consider “gallbladder disease” do not provide adequate numeric data to be 
incorporated into a meta-analysis and are therefore considered only in the qualitative analysis. It was felt that 
“gallbladder disease” was most likely to represent gallstones in these studies given the relative rarity of other 
gallbladder pathologies although caution is needed when considering the findings of these two studies. All of the 
remaining studies define exposure as “gallstone disease”. Three studies report separate outcomes for participants 
with GD who do not undergo cholecystectomy compared to controls and participants who undergo cholecys-
tectomy compared to controls. Five studies report the rate of cholecystectomy which varied from approximately 
31% to 73%. Four studies included only females and three studies included only males. Length of follow-up varied 
from 4.5 to 32 years with a median of 20 years.
Nine studies report adjusted HR of which eight are included in the main analysis (one includes duplication of 
controls from the same database). Two studies reported in the same publication report odds ratio (OR) and are 
considered in the qualitative analysis. Two studies report relative risk (RR) of which one does not report a sample 
size and the studies were therefore considered qualitatively. One study does not report numeric data. Overall this 
review includes over 1,269,137 participants (number of participants not provided in two studies). The quantita-
tive meta-analysis included 1,229,171 participants (186,589 cases and 1,042,582 controls).
Gallstone Disease and the risk of Cardiovascular Disease. Ten of the fourteen studies reported a 
statistically significant increase in CVD due to GD. Three studies report non-statistically significant findings of 
which two demonstrate a trend towards an increase in CVD with GD and one reports a trend towards reduced 
CHD with GD in a female-only cohort. The study reporting no numeric data examined CHD and states: “There 
was no significant relationship with a history of gallbladder disease”.
All Cardiovascular Disease. After controlling for confounding variables participants with GD had a 23% 
increased risk of CVD compared to controls (95% CI = 1.16–1.30, Fig. 2). We identified considerable heteroge-
neity (I2 = 76.3%, p = 0.0001).
Coronary Heart Disease. Seven studies reported CHD as a separate outcome including 843,312 participants 
(56,040 cases and 787,272 controls). Participants with GD had a 24% increased risk of CHD compared to con-
trols (95% CI = 1.16–1.32). We identified considerable heterogeneity when CHD was considered (I2 = 70.7%, 
p = 0.0023).
Figure 1. Flow chart of study selection process
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Cerebrovascular Disease. Four studies reported cerebrovascular disease as a separate outcome although two 
studies used controls from the same database. Three studies were pooled by meta-analysis including 458,518 par-
ticipants (140,844 cases and 317,674 controls). Participants with GD had a 29% increased risk of cerebrovascular 
Author Paul Petitti Bortnichak Bortnichak Grimaldi Ruhl Olaiya Wei Lv Wirth Zheng Zheng Zheng Shabanzdeh
Year 1963 1979 1985 1985 1993 2011 2013 2014 2015 2015 2016 2016 2016 2017
Sex Male Female Male Female Both Both Both Both Both Both Female Female Male Both
Country United  States
United  
States
United  
States United States
United  
States United States Taiwan Taiwan China Germany United States United States United States Denmark
Design Prospective cohort
Prospective 
cohort
Prospective 
cohort
Prospective 
cohort
Prospective 
cohort
Prospective 
cohort
Retrospective 
cohort
Retrospective  
cohort
Prospective 
 cohort
Prospective  
cohort
Prospective  
cohort
Prospective  
cohort
Prospective 
cohort
Prospective 
cohort
Case  
ascer 
tainment
Employees  
of WEC WCCDS FHS FHS GRIC NHANES NHIRD NHIRD CKB EPIC-Germany NHS NHSII HPFS
MONICA - 
Danish
GD  
diagnosis Not stated Not stated
Baseline  
US Baseline US
Cholecy 
stography Baseline US
Inpatient 
insurance  
claims for  
GD
Inpatient HR Self-reported  GD at baseline
Self-reported  
GD at baseline
Self-reported  
GD at baseline
Self-reported  
GD at baseline
Self-reported 
GD at 
baseline
Baseline US
CVD 
diagnosis
Planned  
follow-up 
examination
Self- 
reported 
outcome  
verified in  
HR
HR HR Review  of DC
Review of  
DC
National  
database linkage 
(ICD-9)
National  
database linkage 
(ICD-9)
Linkage to  
DC registry  
and insurance  
registry, active  
follow-up,  
verification of  
HR and DC by  
cardiologist
Postal 
questionnaire,  
HR or DC
HR and DC HR and DC HR and DC
National 
database  
linkage (ICD8 
and  
ICD10)
CVD 
definition CHD
CHD,  
cerebro- 
vascular  
disease,  
VTE
CHD, 
coronary 
insufficiency, 
sudden  
death, (not 
angina 
pectoris)
CHD,  
coronary 
insufficiency, 
sudden  
death,  
(not angina 
pectoris)
Death  
due to  
CVD
Death due 
 to CVD
CHD, 
cerebrovascular 
disease,  
coronary 
insufficiency
Cerebrovascular 
disease CHD
CHD,  
cerebrovascular  
disease
CHD CHD CHD
CHD,  
cerebro- 
vascular  
disease,  
VTE
No.  
Cases Not stated
Not  
stated 180* 322* 222 2018 6981 135512 28345 4828 8796 5227 1449 504
No.  
Control Not stated
Not  
stated 2028 2178 161 12210 27924 271024 459028 41658 103724 107692 42252 4992
Follow-up 
(years) 4.5 6.5 26 26 20 14.7 6 7–10 7.2 8.2 30 22 25 32
Con- 
founder 
adjust- 
ment
Not stated
Smoking, 
age, obesity, 
current OC 
use, previous 
OC use, 
hypertension, 
hyperchol 
esterolaemia, 
alcohol 
consumption
Age,  
smoking, 
obesity, 
hypertension, 
hyperchole 
sterolaemia, 
diabetes 
mellitus,  
LVH
Age,  
smoking, 
obesity, 
hypertension, 
hyperchole 
sterolaemia, 
diabetes 
mellitus,  
LVH
Age, sex, 
diabetes 
mellitus,  
BMI,  
serum 
cholesterol
Age, sex, 
ethnicity, 
education,  
BMI, WHR, 
diabetes  
mellitus, 
HbA1c > 
 6.5%, serum 
cholesterol, 
smoking,  
alcohol 
consumption, 
caffeine 
consumption, 
CRP protein,  
SBP, DBP
Age, sex,  
PVD, 
hyperlipidaemia, 
diabetes mellitus, 
hypertension, 
COPD,  
alcoholism,  
CLD, HHA,  
AHA
Age, sex,  
hypertension,  
diabetes 
mellitus,  
IHD, AF, 
hyperlipidaemia
Age, sex,  
education,  
marital status,  
alcohol  
consumption,  
smoking,  
physical activity, 
red meat intake, 
fruit intake,  
vegetable 
intake, 
hypertension,  
diabetes  
mellitus,  
family history  
IHD, 
menopausal 
status,  
BMI, chronic  
hepatitis,  
cirrhosis, PUD
Age, sex,  
study centre,  
educational  
achievement,  
physical activity,  
smoking, alcohol 
intake, BMI,  
waist 
circumference, 
hypertension,  
hyperlipidaemia
Age, ethnicity,  
family history  
IHD, marital  
status, smoking,  
BMI, physical  
activity, diabetes 
mellitus,  
hypertension, 
hyperchole-
sterolaemia,  
aspirin-use,  
alcohol intake,  
energy-adjusted  
cholesterol- 
intake, 
 energy intake,  
menopausal 
status,  
HRT, OC use
Age,  
ethnicity,  
family history  
IHD, marital  
status, 
smoking,  
BMI, physical  
activity, 
diabetes 
mellitus,  
hypertension, 
hyperchole-
sterolaemia,  
aspirin-use,  
alcohol  
intake, energy- 
adjusted  
cholesterol- 
intake, energy  
intake,  
menopausal 
status,  
HRT, OC use
Age,  
ethnicity,  
family history 
IHD, marital  
status, 
smoking,  
BMI, physical 
activity, 
diabetes 
mellitus,  
hypertension, 
hyperchole-
sterolaemia,  
aspirin-use,  
alcohol 
intake,  
energy- 
adjusted  
cholesterol- 
intake,  
energy intake
Age, sex,  
cohort, BMI,  
SBP, DBP, 
non- 
HDL  
cholesterol,  
HDL,  
smoking,  
alcohol  
consumption,  
diet, physical  
activity,  
social group
Quality 
assessment  
(NOS)
Selection: 2 
Comp-
arability:  
0 Outcome:  
2
Selection: 2 
Comp- 
arability: 1 
Outcome: 2
Selection: 3 
Compa 
rability: 2 
Outcome: 3
Selection: 3 
Comp-
arability: 2 
Outcome: 3
Selection: 2 
Comp-
arability: 1 
Outcome: 3
Selection: 3 
Comp-
arability:  
2 Outcome:  
3
Selection: 4 
Comparability: 2 
Outcome: 1
Selection: 4 
Comparability: 
1 Outcome: 1
Selection: 4  
Comparability:  
1 Outcome: 2
Selection: 2  
Comparability:  
2 Outcome: 1
Selection: 3  
Comparability:  
2 Outcome: 2
Selection: 3  
Comparability:  
2 Outcome: 2
Selection: 3  
Comp-
arability:  
2 Outcome:  
2
Selection: 4  
Comp-
arability:  
2 Outcome:  
3
Table 1. Characteristics of Included Studies. GD: gallstone disease; CVD: cardiovascular disease; NOS: 
Newcastle-Ottawa Scale; US: ultrasound; WEC: Hawthorne Works of the Western Electrical Company 
(Chicago); WCCDS: Walnut Creek Contraceptive Drug Study; FHS: Framingham Heart Study; GRIC: Gila 
River Indian Community; NHANES: National Health and Nutrition Examination Survey; NHIRD: National 
Health Insurance Research Database; CKD: China Kadoorie Biobank; EPIC-Germany: European Prospective 
Investigation into Cancer and Nutrition, German cohorts; NHS: Nurses’ Health Study; NHSII: Nurses’ Health 
Study II; HPFS: Health Professionals Follow-up Study; MONICA: Multinational mONItoring of trends and 
determinants in CArdiovascular disease, Danish cohorts only), HR: hospital records; DC: death certificates; 
ICD-9-CM: International Classification of Diseases, 9th Revision, Clinical Modification; IHD: ischaemic heart 
disease; VTE: venous thromboembolism; MI: myocardial infarction; PVD: peripheral vascular disease; OC: 
oral contraceptive; LVH: left ventricular hypertrophy; BMI: body mass index; WHR: waist-to-hip ratio; CRP: 
C-reactive protein; SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive 
pulmonary disease; CLD: chronic liver disease; HHA: hereditary haemolytic anaemia; AHA: acquired 
haemolytic anaemia; AF: atrial fibrillation; PUD: peptic ulcer disease; HRT: hormone-replacement therapy 
without cholecystectomy excluded from analysis, number of cases remaining in analysis not stated.
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disease compared to controls (95% CI = 1.26–1.32). We did not identify heterogeneity when cerebrovascular 
disease was considered (I2 = 0.00%, p = 0.76).
subgroup Analyses and sensitivity Analyses. We performed subgroup analyses for male-only par-
ticipants, female-only participants, non-diabetic participants, diabetic participants, screen-detected GD and 
symptomatic GD (Table 2). We identified a statistically significant association between GD and CVD in all sub-
groups. One study which reported RR reported a summary estimate <1.00 but was not statistically significant 
and included only 322 cases compared to 103,562 cases included in our meta-analysis. We therefore demonstrate 
that the relationship between GD and CVD is present in both men and women (Fig. 3). The difference between 
diabetic and non-diabetic participants is not statistically significant although a trend towards a stronger effect 
suggests that GD may have a greater relative importance as a predictor of CVD in non-diabetic participants. 
CVD was significantly more common in both screen-detected and symptomatic GD. Heterogeneity remained 
moderate to substantial in all subgroup analyses other than cerebrovascular disease, screen-detected GD and 
cholecystectomy-only.
Two studies from the same database report similar increases in CVD with GD for normotenstive and 
hypertensive participants. One study reports similar increases in CVD with GD for hyperlipidemic and 
non-hyperlipidemic participants. Three studies from the same publication were pooled in a meta-analysis for 
non-obese participants and for non-smokers revealing similar results in both analyses to the overall cohorts. Two 
studies from the same database report HRs for comorbidity-free participants as well as age-stratified subgroups 
for which results are similar to the overall cohorts except in the study assessing effect of GD on cerebrovascular 
where younger and comorbidity-free participants appear to have relatively greater burden of CVD risk. One study 
stratified participants according to GD duration at baseline and found no difference between groups.
We performed sensitivity analyses by iteratively excluding one study from the analysis to detect its impact 
on heterogeneity. Heterogeneity remained substantial for all sensitivity analyses with one study removed. 
Heterogeneity was noted to fall (I2 = 49%) when both Taiwanese studies using data from the same database were 
excluded.
Figure 2. Forest plot demonstrating relationship between GD and CVD. Squares and horizontal lines represent 
individual studies with 95% confidence intervals. Area of squares is proportional to study weighting in random 
effects meta-analysis. Diamond (blue) represents pooled HR from meta-analysis with 95% CI. Reference line 
(black) represents hazard ratio of 1.00 (no association between GD and CVD). Summary line (red) represents 
summary estimate and demonstrates increased risk of CVD with GD (23%).
Subgroup HR (95% CI) P (Cochran Q test) I2 P (Wald-type test) Studies
Sex
Female 1.24 (1.17–1.32) 0.000 77.9%
0.428
5*
Male 1.18 (1.04–1.33) 0.000 90.5% 4*
Diabetes
Diabetic 1.13 (1.06–1.20) NA NA
0.075
1
Non-diabetic 1.23 (1.15–1.32) 0.000 91.3% 6**
Detection of GD
Screen-detected 1.35 (1.17–1.57) 0.847 0.00%
0.183
2
Symptomatic 1.21 (1.15–1.29) 0.000 82.4% 6*
Table 2. Subgroup Analyses for relationship between GD and CVD. Studies which included duplicated 
participants report subgroup results for male and female participants and symptomatic GD, we therefore 
conducted two separate analyses which produced similar results. studies reported in one publication are pooled 
by meta-analysis and both studies which included duplicated participants report subgroup analyses for non-
diabetic participants and we therefore conducted four separate analyses (with and without inclusion of the 
pooled result and with and without each study using duplicated participants) which produced similar results.
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We performed a meta-regression which did not detect any significant effect of follow-up, year of publication, 
quality assessment score, degree of adjustment for confounding variables or variance (p > 0.4 in all cases). In 
addition, none of the explanatory variables accounted for heterogeneity (pseudo-R2 = 0.00%, I2 = 70.4%).
Effect of Cholecystectomy on risk of Cardiovascular Disease. Three studies report separate data for 
cholecystectomy compared to controls and for GD without cholecystectomy compared to controls. One study 
reports a separate analysis of cholecystectomy versus GD without cholecystectomy. Pooled adjusted HR for 
cholecystectomy compared to controls was 1.41 (95%CI: 1.21–1.64) with insignificant heterogeneity (p = 0.250, 
I2 = 27.8%). Pooled adjusted HR for GD without cholecystectomy compared to controls was 1.30 (95%CI:1.07–
1.58) with moderate heterogeneity (p = 0.161, I2 = 45.3%). The study compared cholecystectomy to GD without 
cholecystectomy directly found no statistically significant difference (HR 1.24, 95%CI: 0.85–1.81). One study also 
reported mild GD (cholelithiasis or choledocholithiasis excluding definition of severe GD) and severe GD (acute 
calculous cholecystitis, calculous pancreatitis, cholangitis, surgical procedure for GD or endoscopic procedure 
for GD) and reported a stronger association in mild gallstone disease (HR 1.34, 95%CI: 1.24–1.46 for non-severe 
GD versus HR 1.20, 95%CI: 1.02–1.40 for severe GD).
One report including three cohort studies limited exposure to cholecystectomy only and stated: “CHD risk 
was similar to when our definition of gallstone disease included both history of gallstones and cholecystectomy” 
although does not provide numeric data for this subgroup21. One report including two cohort studies states: 
“Cholecystectomy status proved to be superior to gallstone disease diagnosis in discriminating between those 
individuals who went on to develop coronary disease and those who did not”. This report did not provide data for 
GD with and without cholecystectomy14.
Overall four studies favour a stronger relationship between GD and CVD when cholecystectomy alone is con-
sidered and six studies favour a weaker relationship or no difference. No studies report a statistically significant 
difference between the two groups. Only one study16 adjusted for inflammatory markers (C-reactive protein) and 
found a non-significant trend towards lower risk of CVD in patients undergoing cholecystectomy compared to 
those with gallstones who did not undergo cholecystectomy.
publication Bias. We did not detect publication bias through visual inspection of the funnel plot or by 
Egger’s regression test (p = 0.51, Fig. 4).
Discussion
This systematic review with meta-analysis includes over 1.2 million participants and demonstrates a significant 
association between GD and CVD with an increase of 23% between cases and controls following adjustment for 
confounding variables. The association with GD is present for CHD, cerebrovascular disease and PVD as well 
as for men and women. There is trend towards a relatively stronger association in young and otherwise healthy 
individuals although no subgroup differences were statistically significant. The review highlights a scarcity of high 
quality evidence for the association between cholecystectomy and CVD.
Three separate meta-analyses investigating the relationship between GD and CVD have been published and 
report similar findings to our review with a statistically significant increase in CVD with GD which is present in 
several subgroups21,23,24.
Possible mechanisms linking GD and CVD include dyslipidemia, chronic inflammation and abnormalities in 
the ABCG8 cholesterol transporter gene25–27. Patients with the D19H and T400k polymorphisms of the ABCG8 
gene have been demonstrated to have elevated risk of both CVD and GD suggesting a shared aetiology through 
aberrant cholesterol metabolism28,29. The presence of gallstones is known to be associated with inflammation of 
the gallbladder mucosa7. The presence of inflammation is already known to promote formation of atherosclerotic 
plaques even at distant sites and it is possible that low-grade inflammation associated with gallstones triggers a 
similar response30,31. GD is also associated with obesity, hyperlipidemia, diabetes mellitus and hypertension10,32 
which is responsible in part for an increase in CVD. Adjustment of the reported HR for these confounding 
Figure 3. Forest plot demonstrating relationship between GD and CVD stratified by sex. Blue diamonds 
represent pooled summary estimate with 95% CI for each subgroup and overall pooled estimate for both groups 
combined.
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variables results in a reduction of CVD risk although, in all but two studies the association remains statistically 
significant. Other aetiological mechanisms such as altered gut microbiota and reduced levels of serum insulin-like 
growth factor are implicated in gallstone development and development of atherosclerotic plaques that have not 
been accounted for in any existing studies33–36.
In another meta-analysis, Fan et al. conclude that cholecystectomy is likely to be responsible for increased risk of 
CVD compared to GD without cholecystectomy. They cite evidence of altered serum lipid levels post-cholecystectomy 
in animal models, protective effects of biliary hormones on lipid and glucose metabolism and post-cholecystectomy 
alteration in gut microbiota. We do not feel that the evidence is sufficient to support this hypothesis. Only one cohort 
study makes direct comparison between cholecystectomy and GD without cholecystectomy and finds no significant 
difference. Changing the definition of exposure from GD to cholecystectomy is reported to have no significant impact 
in three studies although numeric data is not provided. Two studies report a trend towards higher rates of CVD fol-
lowing cholecystectomy and one publication reporting two studies only published data for cholecystectomy as this was 
found to be a stronger predictor of CVD than GD as a whole. Three studies found a trend towards a weaker association 
between GD and CVD when cholecystectomy only was considered. Of the studies which find cholecystectomy to be 
a weaker predictor of CVD than GD as a whole, one of these studies16 adjusts for C-reactive protein suggesting that 
inflammation may be responsible for any apparent increase in CVD in the cholecystectomy group. None of the studies 
which demonstrate a trend towards higher rates of CVD in the cholecystectomy group, compared to those with gall-
stones who do not require cholecystectomy, adjust for inflammatory markers. Symptoms arising from inflammation of 
the gallbladder are a key determinant of the need for cholecystectomy, meaning that patients who require cholecystec-
tomy may have suffered from more extensive systemic inflammation. For these reasons we do not feel that cholecystec-
tomy contributes directly to increased risk of CVD and is, instead, more likely to represent those patients who have a 
greater burden from other CVD risk factors.
Our meta-analysis identified substantial heterogeneity for which we did not identify the likely cause. It is possible 
that additional confounding variables at participant- or study-level have not been recorded or reported. A total of five 
studies reported having additional data available, which we were unable to obtain, relating to differences between rate 
of CVD following cholecystectomy compared to GD without cholecystectomy. This suggests that the review may be 
subject to selective reporting bias with only those articles finding a difference between the two comparisons publishing 
the results. Our review identified a persistent direction of effect in all but one study and included data from three studies 
not previously considered in any other review on the same topic. The findings are consistent in several populations and 
subgroups but do not demonstrate a causal link between GD or cholecystectomy and CVD.
Our review has confirmed the significant association between GD and CVD and highlights the importance 
of recognizing GD as a risk factor for CVD. We have demonstrated that risk of CVD is elevated in GD for both 
males and females. We have demonstrated that cholecystectomy may not increase the risk of CVD as previously 
thought. Our review identifies the need for further research into the impact of chronic inflammation on the risk 
of CVD in patients with GD and in particular whether this accounts for any apparent increase in CVD with 
cholecystectomy.
Methods
A systematic review with meta-analysis was undertaken in accordance with the Meta-analysis of Observation 
Studies in Epidemiology (MOOSE) statement37 and the PRISMA statement38.
search strategy. In October 2017 we ran searches in MEDLINE, EMBASE, Science Citation Index and 
Social Sciences Citation Index Expanded and Literatura Latino-americana e do Caribe em Ciências da Saúde 
(LILACS) from earliest date possible. The search strategies are shown in Supplementary Table S1. We combined 
terms into three categories (GD; CVD; and observational studies) using the OR operator before combining the 
three categories using the AND operator.
study selection. We included studies meeting the following criteria:
•	 Longitudinal cohort study
•	 Assessing the relationship between GD and CVD
Figure 4. Funnel plot with pseudo-95% confidence limits. Circles represent identified studies. Log-transformed 
adjusted HR plotted against inverse standard error of log-transformed HR.
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We included cholecystectomy as well as GD without cholecystectomy, we also included screen-detected as 
well as symptomatic GD. Studies which reported “gallbladder disease” and were thought to represent gallstones 
rather than rarer gallbladder pathology were considered only in the qualitative analysis. We included fatal and 
non-fatal CVD events and considered CHD, cerebrovascular disease and peripheral vascular disease (PVD). Each 
subgroup of CVD was considered separately in subanalyses where possible as well as combined into one single 
composite outcome of CVD. No relevant non-English language articles were identified. When identified studies 
were reported in multiple publications we extracted unique data from each publication.
Data extraction. We extracted the following data from each study: authors, publication year, study popu-
lation, baseline characteristics, sample size, study design, country, ascertainment of exposure, detection of CVD 
events, definition of CVD, follow-up duration, confounding variable adjustment, rate of cholecystectomy and 
adjusted effect measures (hazard ratio [HR], relative risk [RR] or odds ratio [OR]) with 95% confidence interval. 
We assessed each study according to the Newcastle-Ottawa Quality Assessment Scale (NOS)39. Prior to data 
extraction we defined an appropriate follow-up period of at least 10 years to allow for CVD events to occur and a 
follow-up rate of >90%. We contacted authors to request additional data when required.
Data Analysis. We assimilated data using DerSimonian-Laird random effects meta-analysis40. We used fully 
adjusted (multivariable) effect measures from each study when available. We did not transform each unique effect 
measures into one single effect measure and as such studies reporting HR, RR or OR are considered in three dis-
tinct groups. All effect measures were log-transformed for purposes of data analysis prior to back-transformation 
for presentation of results.
Subgroup analyses were performed for the following groups:
•	 Male-only participants
•	 Female-only participants
•	 Diabetic participants
•	 Non-diabetic participants
•	 Screen-detected GD
•	 Symptomatic GD
•	 Gallstones (not including cholecystectomy) versus controls
•	 Cholecystectomy only versus controls
Discrete subgroups were compared using a Wald-type test with p value significance set at <0.01. We assessed 
influences of moderator variables by meta-regression using a mixed effects model and the Knapp and Hartung 
adjustment41. For the mixed effects model and meta-regression we included length of follow-up, year of publica-
tion, degree of adjustment for confounding variables, variance and NOS score.
We assessed for presence of heterogeneity using Cochran’s Q test with p value significance set at <0.1 and 
quantified heterogeneity with the I2 statistic42,43. We assessed for the presence of publication bias by visual inspec-
tion of funnel plots and Egger’s regression test with p value significance set at <0.144.
All analyses were undertaken in R version 3.3.1 using the “metafor” package45,46. All data is available in orig-
inal manuscripts.
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